Summary: The objective of this study was to clarify the relationship between the pharmacokinetic parameters of telmisartan and the occurrence of adverse events. In order to perform this study, a total of 1500 adverse events was collected from the eight clinical trials performed in Europe and the United States and the pharmacokinetic parameters (Cmax and AUC) were calculated with the parameters obtained from the population pharmacokinetic model which we have built. Using these data, the pharmacokinetic parameters (Cmax and AUC) were compared between subjects with or without the occurrence of adverse events. The Mann-Whitney test was performed to analyze ten adverse events selected based on the order of frequency. For eight of these ten adverse events, no signiˆcant between-group diŠerence was observed in any pharmacokinetic parameter. For two adverse events, pain and sinusitis, the pharmacokinetic parameters, Cmax and AUC, were greater in subjects with adverse events as compared with those without adverse events, but the intersubject variability of pharmacokinetic parameters was large and there were many subjects in whom C max and AUC were high without any adverse event. These results suggest that there is no clear relationship between pharmacokinetic parameters of telmisartan and the occurrence of adverse events.
Introduction
Telmisartan is a nonpeptide angiotensin II receptor antagonist, 1, 2) which is used for the treatment of hypertension. 3, 4) In order to clarify the pharmacokinetic feature of telmisartan, we have already built and reported a population pharmacokinetic (PPK) model for telmisartan in healthy volunteers and hypertensive patients. 5, 6) The obtained PPK model revealed several factors that could cause the large inter-individual variability in the pharmacokinetics of telmisartan. The PPK analysis also revealed that plasma concentrations of telmisartan obtained from Japanese clinical trials were lower than those obtained from the clinical trials performed in Europe and the United States.
6) The main cause of the diŠerence was concluded to be the diŠerence of food condition, that is, telmisartan was administered orally after food intake in the Japanese studies and before food intake in the other countries' studies. It has already been reported that angiotensin receptor blockers including telmisartan, are well tolerated and have a low incidence of adverse events. 7, 8) In order to evaluate whether the safety of telmisartan would be aŠected by the above-mentioned variability of pharmacokinetics, we investigated the relationship between pharmacokinetic parameters of telmisartan and occurrence of adverse events.
Methods
Data were collected from 1194 subjects enrolled in 8 clinical trials performed in Europe and the United States. The details of these trials are summarized in Table 1 . Trial No. 4 was performed in elderly hypertensive patients at the dose of 20, 40 or 80 mg for 26 ) were performed in hypertensive patients. Hypertensive patients received 20, 40, 80, 120 or 160 mg of telmisartan for 4¿60 weeks. Administrations of telmisartan in these 8 trials were performed before food intake. Placebo control group was included in Trial No. 1, 2 and 3. Trial No. 4, 5, 6 and 7 were performed with active control group (enalapril or lisinopril). The adverse events that occurred in the 8 trials were collected and listed in the order of frequency of their occurrence. Adverse events that occurred in the same subject at diŠerent dosages were counted separately. Though there were two distinct periods for each subject, with or without co-administration of HCTZ, in the drug-drug interaction study (Trial No. 8) , the same adverse event occurring in the diŠerent periods in one subject was counted only once.
We have already built and reported a PPK model for telmisartan using plasma concentration data from trials in Japan, Europe and the United States. 6) Here, the European and United States plasma concentration data from 8 trials (Trial No. 1 to 8) were used to build the PPK model. From this PPK model, individual Bayesian estimates of pharmacokinetic parameters for each patient were obtained using the POSTHOC option in the NONMEM program (ver V, double precision, level 1.0). 15) With these parameters, the individual pharmacokinetic parameters (Cmax and AUC) at the steady state were calculated. The relationship between these calculated pharmacokinetic parameters and the occurrence of ten adverse events based on the order of their frequency was investigated. The relationship between these calculated pharmacokinetic parameters and the occurrence of serious adverse events was also investigated. A``serious'' adverse event was deˆned as any fatal or immediately life-threatening clinical experience, any permanently or severely disabling event, an event that required or prolonged inpatient hospitalization, a congenital anomaly, cancer, or overdose. In addition, the relationship between the Cmax values obtained from the observed plasma concentration proˆles (observed Cmax) and the occurrence of the most frequent event, headache, was investigated.
A non-parametric test (Mann-Whitney test) was used to evaluate the signiˆcance of diŠerences between groups. Data analysis was performed using SYSTAT } (version 7.0; SPSS Science, Chicago, IL) computer software. The criterion of statistical signiˆcance for all analyses was a＝0.05.
Results
The adverse events were collected from a total of 1500 cases, 1194 subjects, in 8 clinical trials.
A total of 1515 adverse events (233 kinds) were observed. Table 2 shows the ranking of the top 10 adverse events. The most frequent adverse event was headache and it occurred in 146 subjects. The results of Mann-Whitney tests are summarized in Table 3 and the box plots of pharmacokinetic parameters (Cmax and AUC) of the subjects with or without the occurrence of adverse events are shown in Fig. 1 . No signiˆcant between-group diŠerences were observed in eight out of ten adverse events. Concerning two events, pain and sinusitis, signiˆcant diŠerences were observed in Cmax and AUC. For these two adverse events, although the Cmax and AUC were greater in the subjects with the occurrence of adverse events compared with those without such occurrence, the intersubject variability was large and more than 10z subjects without event occurrence showed higher exposure than the upper quartile for the respective event-occurred groups.
In six of the clinical trials included in this study, only a few sparse plasma samplings were performed, so the observed Cmax values were obtained from the results of two trials (Trial No. 1 and 8) in which continuous plasma samplings were performed. The result of MannWhitney tests of the analysis using the observed Cmax value and box plot are shown in Table 4 and Fig. 2 . No signiˆcant between-group diŠerence was observed.
In addition, comparison between the groups with serious adverse events and without serious adverse events was performed. ｢All reported Serious adverse events in the 8 trials are listed in Table 5 .｣ As shown in Table 6 and Fig. 3 , no signiˆcant between-group diŠer-ence was observed in any pharmacokinetic parameter.
Discussion
The adverse events were collected from a total of 1500 cases from 8 clinical trials in which all subjects received telmisartan orally over 1 week. It was reported that steady-state plasma concentrations were achieved after approximately 7 days of administration, 4,16) so plasma concentrations would have reached the steady state in these subjects. Therefore, pharmacokinetic parameters in the steady state were used in this study. Adverse events that occurred in the same subject at diŠerent dosages were counted separately, because the diŠerence of exposure might aŠect the occurrence of adverse events. With regard to the co-administration of HCTZ, the previous PPK analysis 6) and the result of a clinical trial 12) revealed that HCTZ did not aŠect the pharmacokinetics of telmisartan, so the adverse events were not classiˆed into groups with or without co-administration of HCTZ. In order to conˆrm the results of these analyses using Cmax and AUC values calculated by the PPK model, observed Cmax values were also used for analysis.
As shown in Table 2 , the most frequent adverse event was headache, which occurred in 146 subjects. It was reported that headache was the most common adverse event in the pooled tolerability data. 8) Most of the top 10 adverse events in this study were the same as in the previous report, 8) suggesting that the adverse events analyzed in this study are common events for telmisartan. No signiˆcant between-group diŠerences were observed in any pharmacokinetic parameter for eight out of the ten adverse events (Table 3) , or in observed Cmax ( Table 4 ). The groups with and without serious adverse events showed no signiˆcant diŠerence in pharmacokinetic parameters ( Table 6 ). Although signiˆcant Subjects with more than one serious adverse event are included. 
The numbers represent mean±S.D. The numbers in parentheses represent numbers of subjects. a) Mann-Whitney test 31 Pharmacokinetics W Adverse Event Analysis of Telmisartan diŠerences in pharmacokinetic parameters were observed for two events, pain and sinusitis, the intersubject variability of pharmacokinetic parameters was large and there were many subjects whose Cmax and AUC were high, who experienced no adverse event (Fig. 1) . Thus, there was no clear relationship between pharmacokinetic parameters and the occurrence of adverse events, or serious adverse events, and increase of exposure does not necessarily result in the occurrence of an adverse event. In this study, we considered adverse events from the viewpoint of safety assessment. In general, side eŠects are symptoms or physiological changes that result directly from the speciˆc biological and pharmacological activity of the drug, and they tend to be dose-dependent and predictable. On the other hand, an adverse event is deˆned as any untoward medical occurrence during a clinical investigation in a subject administered a drug, and so it is not clear if adverse events result directly from the drug's pharmacological activity or not. Therefore, it seems better to analyze the relationship between side eŠects and exposure to a drug than that between adverse eŠects and exposure. However, we could not obtain enough data on side eŠects for analysis, as telmisartan is well tolerated and the occurrence rate of side eŠects of telmisartan is low. Therefore, we investigated the relationship between the occurrence of adverse events and pharmacokinetic parameters.
In the previous report on the PPK model, the AUC and Cmax in Japanese subjects were smaller than those in subjects included in the Europe and United States' clinical trials, mainly due to the diŠerence of food condition.
6) The result of this study suggests that the diŠer-ence of plasma concentrations between Japanese and other countries' clinical data does not have a marked eŠect on the occurrence of adverse events.
It has already been reported that angiotensin receptor blockers including telmisartan, are well tolerated and have a low incidence of adverse events, and the adverse event proˆle is often similar to that of placebo. 7) So it is reasonable that no clear relationship between pharmacokinetic parameters and the occurrence of adverse events was observed, even in 1194 subjects.
If more information about the relationship between side eŠects, not adverse events, and plasma concentrations were collected, it might prove useful to predict the occurrence of side eŠects from the plasma concentration.
In conclusion, the relationship between pharmacokinetic parameters of telmisartan and the occurrence of adverse events was investigated based on a total of 1500 cases from 8 clinical trials. For most of the adverse events, no signiˆcant diŠerence in pharmacokinetic parameters between subjects with and without occurrence of adverse events was observed. Even in the case of adverse events that were found to have a signiˆcant diŠerence, there were many subjects without any adverse event whose pharmacokinetic parameters were higher than those of subjects showing an adverse event. These results suggest that there is no clear relationship between pharmacokinetic parameters and the occurrence of adverse events.
